Review Article
Toxicities Associated with Cisplatin-Based Chemotherapy and Radiotherapy in Long-Term Testicular Cancer Survivors
Table 2
Relative risks of second malignant neoplasms (SMN) in testicular cancer survivors.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adapted with permission from Fung et al. J Natl Compr Canc Netw 2012; 10:545-56 (Table 2). RR: relative risk; CI: confidence interval; Obs.: observed number of cases; RT: any radiation treatment; CT: chemotherapy; IDRT: infradiaphragmatic radiation; SDRT: supradiaphragmatic radiation; MRT: mediastinal radiation; PVB: cisplatin, vinblastine, bleomycin; BEP: bleomycin, etoposide, cisplatin; N/A: not available (data not provided). (a) There was overlap in the cancer registries included in the cohort studies by Richiardi et al. [164] and Travis et al. [55], with the following countries contributing patients to both studies: Denmark, Finland, Norway, and Sweden; (b) six cases of leukemia were observed with a RR of 1.9 (95% CI: 0.7–4.1); (c) thirty-eight cases of myeloid leukemia were observed with a RR of 3.6 (95% CI: 2.6–5.0); thirteen cases of lymphoid leukemia were observed with a RR of 1.0 (95% CI: 0.5–1.7); twenty-three cases of other types of leukemia were observed with a RR of 3.5 (95% CI: 2.2–5.2); (d) six cases of leukemia were observed with a RR of 1.6 (95% CI: 0.6–3.5); (e) hazard ratios are shown, with the referent group consisting of patients treated with surgery alone (HR = 1.0). Twelve cases of leukemia were observed with a RR of 3.8 (95% CI: 2.0–6.7); (f) significantly increased risks occurred for cancers of the kidney (SIR = 3.4; 95% CI 1.8–5.7; n = 13); thyroid (SIR = 4.4; 95% CI: 2.2–7.9; n = 11); and soft tissue (SIR = 7.5; 95% CI: 3.6–13.8; n = 10). |